MelliCell, Inc.
Biotechnology ResearchMassachusetts, United States11-50 Employees
MelliCell develops therapeutics for chronic disease using proprietary technologies that model weight gain in human fat cells in vitro. Our core technology enables discovery of novel therapeutic targets and drugs that can overcome the limitations of existing therapies and correct fat cell dysfunction that causes chronic disease. Our technology efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes and disease hallmarks of fat cells in patients. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts chronic disease better than obesity per se. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.
1-888-653-2347 
support@leadiq.com 
